Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo

Of 907 participants, 25.9% had a BMI <25 kg/m, 50.5% had a BMI ≥25 to <30 kg/m, and 23.6% had a BMI ≥30 kg/m.

• Tirzepatide treatment resulted in a greater reduction in mean glycated haemoglobin (HbA1c) ranging from -2.0% to -2.8%, compared to insulin glargine's reduction of -0.8% to -1.0%.
• Percent change in body weight decreased by -5.5% to -10.8% with tirzepatide, while insulin glargine was associated with a weight increase of 1.0% to 2.5%.
• A higher proportion of participants treated with tirzepatide achieved treatment goals for both HbA1c and body weight reduction compared to those on insulin glargine.
• Improvements in other cardiometabolic indicators were noted with tirzepatide across all BMI subgroups.
• The safety profile of tirzepatide was similar across BMI subgroups, with gastrointestinal-related events and decreased appetite being the most common adverse effects.

AI simplified